More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$60364723
EPS
-0.37
P/E ratio
--
Price to sales
1.3
Dividend yield
--
Beta
1.033821
Previous close
$5.29
Today's open
$5.27
Day's range
$4.89 - $5.40
52 week range
$4.30 - $12.94
show more
CEO
Nicholas T. Curtis
Employees
150
Headquarters
Orlando, FL
Exchange
NASDAQ Capital Market
Shares outstanding
12294241
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
LENSAR Q3 Earnings Call Highlights
LENSAR NASDAQ: LNSR reported a slight decline in third-quarter revenue as lower sales of its cataract surgery systems offset growth in procedure and other recurring revenue. The company said its installed base and procedure volume continued to expand, while its operating loss narrowed from a year earlier.
MarketBeat • Nov 10, 2026

LENSAR, Inc. (LNSR) Q3 2026 Earnings Call Transcript
LENSAR, Inc. (LNSR) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 10, 2026

LENSAR® Reports Third Quarter 2026 Financial Results and Provides Business Update
10 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in Third Quarter 2026; Backlog of 12 ALLY Systems as of September 30, 2026 Third Quarter Recurring Revenue Grew 17% Year Over Year to $12.6 Million Total Laser Installed Base Reaches 450 Systems; ALLY System Installed Base Expands 22% Year Over Year ORLANDO, Fla., Nov. 10, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2026 and provided an update on key operational initiatives.
GlobeNewsWire • Nov 10, 2026

LENSAR® to Report Third Quarter 2026 Results on November 10th, 2026
ORLANDO, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's third quarter 2026 financial results will be released before market open on Tuesday, November 10, 2026.
GlobeNewsWire • Nov 3, 2026

Cedar Grove Capital Q3 2026 Portfolio Update
During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. During the quarter, we closed short positions in Bending Spoons SpA, Chipotle Mexican Grill, The Ensign Group, Gemini Space Station, Jersey Mike's Subs, Moderna, Reformation, Once Upon a Farm, and X-Energy Inc. We initiated a small tracking position in Zedcor Inc. while continuing our due diligence.
Seeking Alpha • Oct 7, 2026

LENSAR Q2 Earnings Call Highlights
LENSAR NASDAQ: LNSR reported second-quarter 2026 revenue growth of 18% as the company continued to rebuild commercial momentum following the termination of its proposed merger with Alcon near the end of the first quarter.
MarketBeat • Aug 13, 2026

LENSAR, Inc. (LNSR) Q2 2026 Earnings Call Transcript
LENSAR, Inc. (LNSR) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 13, 2026

LENSAR® Reports Second Quarter 2026 Results and Provides Business Update
10 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in Second Quarter 2026; Backlog of 13 ALLY Systems as of June 30, 2026 Second Quarter Recurring Revenue was $13.7 million Total Laser Installed Base Climbs to 445 Systems, Driven by 30% Growth in ALLY Placements ORLANDO, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2026 and provided an update on key operational initiatives.
GlobeNewsWire • Aug 13, 2026

LENSAR Q1 Earnings Call Highlights
LENSAR NASDAQ: LNSR executives told investors on Thursday that the company is moving past a “transaction-related holding pattern” after the termination of its planned merger, and is now refocusing on rebuilding commercial momentum around its ALLY femtosecond laser cataract platform. Management said first-quarter results reflected that period of uncertainty, but highlighted continued growth in recurring revenue and rising procedure volumes.
MarketBeat • May 8, 2026

LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript
LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript
Seeking Alpha • May 8, 2026

¹ Disclosures

Open an M1 investment account to buy and sell LENSAR Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.